Lessons to be learned from a complicated case of rhino-cerebral mucormycosis in a renal allograft recipient

Transplant International

Volumn 16, Issue 12, 2003, Pages 885-889

  Ladurner, Ruth ^a   Brandacher, Gerald ^a   Steurer, Wolfgang ^a   Schneeberger, Stefan ^a   Bösmüller, Claudia ^a   Freund, Martin Clemens ^a   Kreczy, Alfons ^b   Königsrainer, Alfred ^a   Margreiter, Raimund ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Fungal infection; Immunosuppression; Mucormycosis; Rhino cerebral infection

Indexed keywords

AMPHOTERICIN B; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BIOPSY; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CHILD; DEBRIDEMENT; DIAGNOSTIC TEST; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FATALITY; FUNGUS HYPHAE; GRAFT REJECTION; HUMAN; KIDNEY ALLOGRAFT; MALE; MUCORMYCOSIS; PARANASAL SINUS; PRIORITY JOURNAL; RECIPIENT; RHINOCEREBRAL MUCORMYCOSIS; SURGICAL APPROACH;

EID: 0346257962     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-003-0648-5     Document Type: Article

References (21)

1. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis. Arch Intern Med 1999; 159:1301.
2. Lehrer RI, Howard DH, Sypherd PS, Edwards JE, Segal GP, Winston DJ. Mucormycosis. Ann Intern Med 1980; 93:93.
3. Boelaert JR. Mucormycosis (zygomycosis): is there news for the clinician? J Infect 1994; 28 (Suppl 1): 1.
4. Sugar AM. Mucormycosis. Clin Infect Dis 1992; 14 (Suppl 1): 126.
5. Yeung CK, Cheng VC, Lie AK, Yuen KY. Invasive disease due to mucorales: a case report and review of the literature. Hong Kong Med J 2001; 7:180.
6. Sokolo R, Lefort T, Soulhiard F, Dumollard LM, Seguin P. Paranasal mucormycosis with involvement of the sphenoid sinus (in French). Rev Stomatol Chir Maxillofac 1998; 99:52.
7. Warwar RE, Bullock JD. Rhino-orbital-cerebral mucormycosis: a review. Orbit 1998; 17:237.
8. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42:216.
9. Tunkel AR, Scheld WM. Central nervous system infection in the immunocompromised host. In: Rubin RH, Lowell SY, eds. Clinical approach to infection in the immunocompromised host, 3rd edn. Plenum Medical Book Company, New York, 1994:163.
10. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741.
11. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236.
12. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59:240.
13. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999; 17:554.
14. Iacoangeli M, Roselli R, Antinori A, et al. Experience with brain biopsy in acquired deficiency syndrome-related focal lesions of the central nervous system. Br J Surg 1994; 81:1508.
15. Gupta AK, Mann SB, Khosla VK, Sastry KV, Hundal JS. Non-randomized comparison of surgical modalities for paranasal sinus mycoses with intracranial extension. Mycoses 1999; 42:225.
16. Ochi JW, Harris JP, Feldmann JI, Press GA. Rhinocerebral mucormycosis: results of aggressive surgical debridement and amphotericin B. Laryngoscope 1988; 98:1339.
17. Hoang A. Caspofungin acetate: an antifungal agent. Am J Health Pharm 2001; 58:1206.
18. Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61:1121.
19. Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000; 44:368.
20. Voitl P, Scheibenpflug C, Weber T, Janata O, Rokitansky AM. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 2002; 21:632.
21. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itroconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from Sentry Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46:1032.